GlassScriptPhysician profile
Charles S Kaplan
NPI 1538117536
$429.91
in general payments reported to CMS, 2019-2025
14 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.78 · 2022: $55.78 · 2023: $114 · 2024: $124 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $63.98 | 2019-2025 | Watchman Flx |
| Ferring Pharmaceuticals INC. | $47.32 | 2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $43.94 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $39.33 | 2023-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $36.48 | 2023 | Shingrix, Arexvy |
| Pfizer INC. | $31.20 | 2024 | |
| Amgen INC. | $31.06 | 2023 | Evenity, Prolia |
| Corium, LLC | $27.05 | 2023 | Adlarity |
| Medtronic, INC. | $23.60 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.98 | 2024 | Spravato |
| Pharmacosmos Therapeutics INC. | $19.21 | 2024 | Monoferric |
| Nestle Healthcare Nutrition INC. | $19.18 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.58 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.